Poland· PL-100529711
Kyinsu
A insulins and analogues for injection, long-acting product containing insulinum icodec + semaglutidum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Insulinum icodec + semaglutidum is registered in 5 of 19 countries.
Countries holding a registration under ATC A10AE (insulins and analogues for injection, long-acting), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Insulinum icodec + semaglutidum · ATC A10AE
5 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Insulinum icodec + Semaglutidum
- Manufacturer
- Novo Nordisk A/S
- Country
- Poland (PL)
- ATC code
- A10AE
- ATC class
- Insulins and analogues for injection, long-acting
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulinum icodec + semaglutidum in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYINSUNovo Nordisk A/S, Bagsvaerd
- FinlandKyinsuNovo Nordisk A/S
- IrelandKyinsu (700 units + 2 mg)/mL solution for injection in pre-filled penNovo Nordisk A/S
- IcelandKyinsuNovo Nordisk A/S
- NetherlandsKyinsu (700 eenheden + 2 mg)/ml oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
- SwedenKyinsu 700 IE/ml + 2 mg/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kyinsu
- Norway · Kyinsu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/71be7a02-d827-4a7e-9d01-dc1f3cad4f6a GET /v1/drugs/71be7a02-d827-4a7e-9d01-dc1f3cad4f6a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "(700 j.m. + 2 mg)/ml",
"packaging": "Rp ¦ EU/1/25/1992/001 ¦ 164954\n1 wstrzykiwacz 0,43 ml\nRp ¦ EU/1/25/1992/002 ¦ 164955\n1 wstrzykiwacz 0,43 ml ¦ 6 igieł \nRp ¦ EU/1/25/1992/003 ¦ 164956\n1 wstrzykiwacz 1 ml\nRp ¦ EU/1/25/1992/004 ¦ 164957\n1 wstrzykiwacz 1 ml ¦ 9 igieł \nRp ¦ EU/1/25/1992/005 ¦ 164958\n1 wstrzykiwacz 1,5 ml\nRp ¦ EU/1/25/1992/006 ¦ 164959\n1 wstrzykiwacz 1,5 ml ¦ 9 igieł",
"substance": "Insulinum icodec 700 j.m./ml + Semaglutidum 2 mg/ml",
"common_name": "Insulinum icodec + Semaglutidum",
"pl_product_id": "100529711",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about insulinum icodec + semaglutidum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.